BridgeBio Oncology Therapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $396.5K | $332.9K | $250.0K |
| FY2024 | $19.6M | $164.3M | $30.9M |
| FY2025 | $37.3M | $448.4M | $373.7M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2023 | $396.5K | $332.9K | $250.0K |
| FY2024 | $19.6M | $164.3M | $30.9M |
| FY2025 | $37.3M | $448.4M | $373.7M |